ArticleAnalytical and bioanalytical chemistry2026
MSIDAT: an automated platform for improved metabolite annotation in mass spectrometry imaging via mass shift evaluation and customized databases.
Article in Analytical and bioanalytical chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Spatially resolved metabolomics based on mass spectrometry imaging (MSI) enables in situ characterization of tissue-specific metabolic functions by mapping the spatial distribution of metabolites. However, accurate metabolite annotation and automated analysis of large-scale MSI data remain challenging, mainly due to mass-to-charge ratio (m/z) shifts and dependence on generic databases. To address these challenges, we developed the MSI Data Analysis Tool (MSIDAT), an automated and user-friendly MSI data processing platform. By integrating liquid chromatography-tandem mass spectrometry (LC-MS/MS)-assisted metabolite identification, customized metabolite ion databases can be constructed to improve the specificity and reliability of metabolite annotation. In addition, m/z shifts in MSI data were systematically evaluated using endogenous reference ions by calculating the relative mass error between theoretical and measured m/z values, enabling adaptive mass tolerance correction. Based on this strategy, mass error-informed metabolite matching and putative annotation were achieved. Furthermore, MSIDAT provides flexible parameter settings, modular workflows, and open-source accessibility, facilitating efficient and reproducible MSI data analysis. The performance of the platform was demonstrated in a clinical cohort of rectal cancer patients, in which hundreds of metabolites were putatively annotated and spatial alterations in tumor-associated metabolites were observed, suggesting fatty acid-related metabolic alterations. Overall, this study presents a robust and versatile analytical platform for improving metabolite annotation in MSI, thereby enhancing data mining efficiency and supporting spatial metabolomics-driven biomarker discovery and clinical applications.
Indexed as
Identifiers
42201349What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.